Loss of exclusivityFebruary 2044latest FDA-listed patent expiry
CompanyAmivas →See this company's full patent-cliff portfolio
Drug detail
Brand name
ARTESUNATE
Active ingredient
ARTESUNATE
Strength
110MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
Modality
Small molecule
FDA approval
May 2020
Marketing status
RX
Listed patents
Patent
Expires
Type
12390442
February 2044
use U-4433
12121506
February 2044
product
Regulatory exclusivity
Code
Expires
ODE-290
May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.